Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.59 |
| ▸ | MEN1 | O00255 | 3/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.56 |
| ▸ | MAPT | P10636 | 3/20 | 0.56 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.56 |
| ▸ | DRD2 | P14416 | 9/20 | 0.55 |
| ▸ | HTR2A | P28223 | 9/20 | 0.55 |
| ▸ | DRD3 | P35462 | 9/20 | 0.55 |
| ▸ | LMNA | P02545 | 2/20 | 0.54 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.53 |
| ▸ | XBP1 | P17861 | 1/20 | 0.53 |
| ▸ | HTT | P42858 | 1/20 | 0.53 |
| ▸ | TSHR | P16473 | 1/20 | 0.51 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3143481 | 1.00 | POLB (0.60) | POLBALDH1A1SMN1; SMN2MEN1KMT2A | |
| SCHEMBL1969239 | 0.93 | POLB (0.58) | POLBALDH1A1SMN1; SMN2MEN1KMT2A | |
| SCHEMBL1966066 | 0.93 | POLB (0.63) | POLBALDH1A1SMN1; SMN2MEN1KMT2A | |
| SCHEMBL3133106 | 0.93 | POLB (0.58) | POLBALDH1A1SMN1; SMN2MEN1KMT2A | |
| SCHEMBL3148109 | 0.93 | POLB (0.63) | POLBALDH1A1SMN1; SMN2MEN1KMT2A | |
| SCHEMBL1971379 | 0.91 | POLB (0.60) | POLBALDH1A1SMN1; SMN2MEN1KMT2A | |
| SCHEMBL3134872 | 0.91 | POLB (0.60) | POLBALDH1A1SMN1; SMN2MEN1KMT2A | |
| SCHEMBL3148400 | 0.89 | DRD3 (0.62) | POLBALDH1A1SMN1; SMN2MEN1KMT2A | |
| SCHEMBL1972542 | 0.89 | DRD3 (0.62) | POLBALDH1A1SMN1; SMN2MEN1KMT2A | |
| SCHEMBL3134267 | 0.87 | DRD2 (0.60) | POLBALDH1A1SMN1; SMN2MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2334644-A1 | PYRIDINYLPIPERAZIN DERIVATIVES USEFUL AS MODULATORS OF DOPAMINE D3 RECEPTORS | F. Hoffmann-La Roche AG (CH) | 2011-06-22 | — | — | EP | claimed |
| WO-2010034648-A1 | PYRIDINYLPIPERAZIN DERIVATIVES USEFUL AS MODULATORS OF DOPAMINE D3 RECEPTORS | F. HOFFMANN-LA ROCHE AG (CH) | 2010-04-01 | — | — | WO | claimed |
| US-20100075979-A1 | PYRIDINYLPIPERAZIN DERIVATIVES USEFUL AS MODULATORS OF DOPAMINE D3 RECEPTORS | HOFFMANN-LA ROCHE, INC. | 2010-03-25 | — | — | US | claimed |
| EP-2334644-A1 | PYRIDINYLPIPERAZIN DERIVATIVES USEFUL AS MODULATORS OF DOPAMINE D3 RECEPTORS | F. Hoffmann-La Roche AG (CH) | 2011-06-22 | — | — | EP | disclosed |
| WO-2010034648-A1 | PYRIDINYLPIPERAZIN DERIVATIVES USEFUL AS MODULATORS OF DOPAMINE D3 RECEPTORS | F. HOFFMANN-LA ROCHE AG (CH) | 2010-04-01 | — | — | WO | disclosed |
| US-20100075979-A1 | PYRIDINYLPIPERAZIN DERIVATIVES USEFUL AS MODULATORS OF DOPAMINE D3 RECEPTORS | HOFFMANN-LA ROCHE, INC. | 2010-03-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100075979-A1 | PYRIDINYLPIPERAZIN DERIVATIVES USEFUL AS MODULATORS OF DOPAMINE D3 RECEPTORS | DRD3, DRD2, VDR | POLB 3954/4885ALDH1A1 1867/4885SMN1; SMN2 3334/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.